000127047 001__ 127047
000127047 005__ 20240228140903.0
000127047 0247_ $$2doi$$a10.3324/haematol.2015.124115
000127047 0247_ $$2pmid$$apmid:25795721
000127047 0247_ $$2pmc$$apmc:PMC4450628
000127047 0247_ $$2ISSN$$a0390-6078
000127047 0247_ $$2ISSN$$a1592-8721
000127047 0247_ $$2altmetric$$aaltmetric:3815689
000127047 037__ $$aDKFZ-2017-03073
000127047 041__ $$aeng
000127047 082__ $$a610
000127047 1001_ $$aMai, Elias K$$b0
000127047 245__ $$aA magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
000127047 260__ $$aPavia$$bFerrata Storti Foundation$$c2015
000127047 3367_ $$2DRIVER$$aarticle
000127047 3367_ $$2DataCite$$aOutput Types/Journal article
000127047 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522317630_19475
000127047 3367_ $$2BibTeX$$aARTICLE
000127047 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127047 3367_ $$00$$2EndNote$$aJournal Article
000127047 520__ $$aDiffuse and focal bone marrow infiltration patterns detected by magnetic resonance imaging have been shown to be of prognostic significance in all stages of monoclonal plasma cell disorders and have, therefore, been incorporated into the definition of the disease. The aim of this retrospective analysis was to develop a rapidly evaluable prognostic scoring system, incorporating the most significant information acquired from magnetic resonance imaging. Therefore, the impact of bone marrow infiltration patterns on progression-free and overall survival in 161 transplant-eligible myeloma patients was evaluated. Compared to salt and pepper/minimal diffuse infiltration, moderate/severe diffuse infiltration had a negative prognostic impact on both progression-free survival (P<0.001) and overall survival (P=0.003). More than 25 focal lesions on whole-body magnetic resonance imaging or more than seven on axial magnetic resonance imaging were associated with an adverse prognosis (progression-free survival: P=0.001/0.003 and overall survival: P=0.04/0.02). A magnetic resonance imaging-based prognostic scoring system, combining grouped diffuse and focal infiltration patterns, was formulated and is applicable to whole-body as well as axial magnetic resonance imaging. The score identified high-risk patients with median progression-free and overall survival of 23.4 and 55.9 months, respectively (whole-body-based). Multivariate analyses demonstrated that the magnetic resonance imaging-based prognostic score stage III (high-risk) and adverse cytogenetics are independent prognostic factors for both progression-free and overall survival (whole-body-based, progression-free survival: hazard ratio=3.65, P<0.001; overall survival: hazard ratio=5.19, P=0.005). In conclusion, we suggest a magnetic resonance imaging-based prognostic scoring system which is a robust, easy to assess and interpret parameter summarizing significant magnetic resonance imaging findings in transplant-eligible patients with multiple myeloma.
000127047 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000127047 588__ $$aDataset connected to CrossRef, PubMed,
000127047 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000127047 7001_ $$0P:(DE-HGF)0$$aKloth, Jost K$$b2
000127047 7001_ $$0P:(DE-HGF)0$$aMerz, Maximilian$$b3
000127047 7001_ $$aShah, Sofia$$b4
000127047 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b5$$udkfz
000127047 7001_ $$aHillengass, Michaela$$b6
000127047 7001_ $$aWagner, Barbara$$b7
000127047 7001_ $$aJauch, Anna$$b8
000127047 7001_ $$aHose, Dirk$$b9
000127047 7001_ $$0P:(DE-He78)5d10a98475a036b2a1ad3c2316d4b3ab$$aWeber, Marc-André$$b10$$udkfz
000127047 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b11$$udkfz
000127047 7001_ $$aGoldschmidt, Hartmut$$b12
000127047 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b13$$eLast author$$udkfz
000127047 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2015.124115$$gVol. 100, no. 6, p. 818 - 825$$n6$$p818 - 825$$tHaematologica$$v100$$x1592-8721$$y2015
000127047 909CO $$ooai:inrepo02.dkfz.de:127047$$pVDB
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5d10a98475a036b2a1ad3c2316d4b3ab$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000127047 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000127047 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000127047 9141_ $$y2015
000127047 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127047 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127047 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127047 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000127047 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000127047 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000127047 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127047 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127047 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127047 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127047 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127047 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127047 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127047 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127047 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x1
000127047 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x2
000127047 980__ $$ajournal
000127047 980__ $$aVDB
000127047 980__ $$aI:(DE-He78)C060-20160331
000127047 980__ $$aI:(DE-He78)E010-20160331
000127047 980__ $$aI:(DE-He78)G170-20160331
000127047 980__ $$aUNRESTRICTED